RrgB321, a Fusion Protein of the Three Variants of the Pneumococcal Pilus Backbone RrgB, Is Protective In Vivo and Elicits Opsonic Antibodies

ABSTRACT Streptococcus pneumoniae pilus 1 is present in 30 to 50% of invasive disease-causing strains and is composed of three subunits: the adhesin RrgA, the major backbone subunit RrgB, and the minor ancillary protein RrgC. RrgB exists in three distinct genetic variants and, when used to immunize mice, induces an immune response specific for each variant. To generate an antigen able to protect against the infection caused by all pilus-positive S. pneumoniae strains, we engineered a fusion protein containing the three RrgB variants (RrgB321). RrgB321 elicited antibodies against proteins from organisms in the three clades and protected mice against challenge with piliated pneumococcal strains. RrgB321 antisera mediated complement-dependent opsonophagocytosis of piliated strains at levels comparable to those achieved with the PCV7 glycoconjugate vaccine. These results suggest that a vaccine composed of RrgB321 has the potential to cover 30% or more of all pneumococcal strains and support the inclusion of this fusion protein in a multicomponent vaccine against S. pneumoniae.

[1]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[2]  S. Madhi,et al.  Review on the immunogenicity and safety of PCV-13 in infants and toddlers , 2011, Expert review of vaccines.

[3]  C. Donati,et al.  The Streptococcus pneumoniae Pilus-1 Displays a Biphasic Expression Pattern , 2011, PloS one.

[4]  N. Andrews,et al.  Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study , 2011, PLoS medicine.

[5]  V. Masignani,et al.  Structural and Functional Characterization of the Streptococcus pneumoniae RrgB Pilus Backbone D1 Domain* , 2011, The Journal of Biological Chemistry.

[6]  K. Jansen,et al.  Multilaboratory Comparison of Streptococcus pneumoniae Opsonophagocytic Killing Assays and Their Level of Agreement for the Determination of Functional Antibody Activity in Human Reference Sera , 2010, Clinical and Vaccine Immunology.

[7]  J. Poolman,et al.  Preclinical Evaluation of the Pht Proteins as Potential Cross-Protective Pneumococcal Vaccine Antigens , 2010, Infection and Immunity.

[8]  R. Adegbola,et al.  Serotype-Related Variation in Susceptibility to Complement Deposition and Opsonophagocytosis among Clinical Isolates of Streptococcus pneumoniae , 2010, Infection and Immunity.

[9]  C. Donati,et al.  The Two Variants of the Streptococcus pneumoniae Pilus 1 RrgA Adhesin Retain the Same Function and Elicit Cross-Protection In Vivo , 2010, Infection and Immunity.

[10]  R. Rappuoli,et al.  Supramolecular Organization of the Repetitive Backbone Unit of the Streptococcus pneumoniae Pilus , 2010, PloS one.

[11]  M. Nahm,et al.  Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. , 2010, Microbiology.

[12]  V. Masignani,et al.  Prevalence of pilus-encoding islets among acute otitis media Streptococcus pneumoniae isolates from Israel. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  R. Rappuoli,et al.  Molecular architecture of Streptococcus pneumoniae TIGR4 pili , 2009, The EMBO journal.

[14]  R. Prymula,et al.  10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™ , 2009, Expert review of vaccines.

[15]  R. Dagan.  Serotype replacement in perspective. , 2009, Vaccine.

[16]  P. Paradiso.  Essential criteria for evaluation of pneumococcal conjugate vaccine candidates. , 2009, Vaccine.

[17]  I. Feavers,et al.  Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. , 2009, Vaccine.

[18]  S. Meri,et al.  Streptococcus pneumoniae Capsular Serotype 19F Is More Resistant to C3 Deposition and Less Sensitive to Opsonophagocytosis than Serotype 6B , 2008, Infection and Immunity.

[19]  G. Jönsson,et al.  Impaired Opsonization with C3b and Phagocytosis of Streptococcus pneumoniae in Sera from Subjects with Defects in the Classical Complement Pathway , 2008, Infection and Immunity.

[20]  W. Hanage,et al.  Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. , 2008, The Journal of infectious diseases.

[21]  R. Rappuoli,et al.  Pneumococcal Pili Are Composed of Protofilaments Exposing Adhesive Clusters of Rrg A , 2008, PLoS pathogens.

[22]  M. Kalin,et al.  Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies , 2008, The Journal of experimental medicine.

[23]  M. Ramirez,et al.  The presence of the pilus locus is a clonal property among pneumococcal invasive isolates , 2008, BMC Microbiology.

[24]  K. O'Brien,et al.  Association of the Pneumococcal Pilus with Certain Capsular Serotypes but Not with Increased Virulence , 2007, Journal of Clinical Microbiology.

[25]  In Ho Park,et al.  Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae , 2007, Journal of Clinical Microbiology.

[26]  R. Rappuoli,et al.  Streptococcus pneumoniae Pilus Subunits Protect Mice against Lethal Challenge , 2006, Infection and Immunity.

[27]  D. Briles,et al.  Development of a Vaccine against Invasive Pneumococcal Disease Based on Combinations of Virulence Proteins of Streptococcus pneumoniae , 2006, Infection and Immunity.

[28]  Robert L. Burton,et al.  Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies , 2006, Clinical and Vaccine Immunology.

[29]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[30]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[31]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[32]  M. Nahm,et al.  Efficiency of a Pneumococcal Opsonophagocytic Killing Assay Improved by Multiplexing and by Coloring Colonies , 2003, Clinical Diagnostic Laboratory Immunology.

[33]  Theresa M. Wizemann,et al.  Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection , 2001, Infection and Immunity.

[34]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[35]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. , 2000, The Pediatric infectious disease journal.

[37]  J. Claverys,et al.  Development of competence in Streptococcus pneumoniae: pheromone autoinduction and control of quorum sensing by the oligopeptide permease , 1998, Molecular microbiology.

[38]  C. Rosenow,et al.  Contribution of novel choline‐binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae , 1997, Molecular microbiology.

[39]  L. McDaniel,et al.  PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type , 1991, Infection and immunity.

[40]  M. Hostetter,et al.  Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. , 1986, The Journal of infectious diseases.

[41]  E. Brown,et al.  The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. , 1983, Reviews of infectious diseases.

[42]  J. Paton,et al.  Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae , 1983, Infection and immunity.

[43]  J. Winkelstein,et al.  The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. , 1976, Journal of immunology.